Brief: ORIC Pharmaceuticals Q4 Net Income USD -28.33 Million
11/03/2024 20:05
Mar 11 (Reuters) - ORIC Pharmaceuticals Q4 basic EPS USD -0.49 vs. IBES estimate USD -0.49. * Q4 operating expenses USD 31.428 million * Q4 income from operations USD -31.428 million
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows